Request Demo
Last update 08 May 2025
Xuesaitong Enteric-coated Tablets
Last update 08 May 2025
Overview
Basic Info
Drug Type Herbal medicine |
Synonyms- |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
7
Clinical Trials associated with Xuesaitong Enteric-coated TabletsNCT03072121
Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy
NCT03072082
Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy
CTR20130562
血塞通肠溶片治疗冠心病心绞痛-心血瘀阻证随机、双盲、阳性药平行对照多中心Ⅱ期临床试验
[Translation] A randomized, double-blind, positive-drug parallel-controlled, multicenter phase II clinical trial of Xuesetong enteric-coated tablets in the treatment of angina pectoris in coronary heart disease and blood stasis syndrome
100 Clinical Results associated with Xuesaitong Enteric-coated Tablets
Login to view more data
100 Translational Medicine associated with Xuesaitong Enteric-coated Tablets
Login to view more data
100 Patents (Medical) associated with Xuesaitong Enteric-coated Tablets
Login to view more data
100 Deals associated with Xuesaitong Enteric-coated Tablets
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Brain Infarction | Phase 3 | China | 08 Oct 2015 | |
| Angina Pectoris | Phase 2 | China | 23 Apr 2012 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | 24 | ehmydjdhtp(rhnzberlma) = The incidence of adverse events (AEs) was similar between formulations (50-60% had at least 1 AE). All AEs occurring during the treatment period were grade 1 or 2 and resolved by the time of follow up. Headache was the most common AE, reported in 50% of subjects. No rash AEs were reported. tpatmhsndz (mhfxoorxxb ) | - | 01 Jan 2011 | ||
2x100-mg non-coated tablets |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free